Special Alerts:
[Posted 10/18/2007] FDA informed healthcare professionals of reports of sudden decreases or loss of hearing following the use of PDE5 inhibitors sildenafil (Viagra), tadalafil (Levitra), vardenafil (Cialis) for the treatment of erectile dysfunction, and sildenafil (Revatio) for the treatment of pulmonary arterial hypertension. In some cases, the sudden hearing loss was accompanied by tinnitus and dizziness. Medical follow-up on these reports was often limited which makes it difficult to determine if the loss of hearing was related to the use of one of the drugs, an underlying medical condition or other risk factors for hearing loss, a combination of these factors or other factors. The PRECAUTIONS and ADVERSE REACTIONS sections of the approved product labeling for sildenafil (Viagra), tadalafil, and vardenafil were revised. FDA is working with the manufacturer to revise the labeling for sildenafil (Revatio). For more information visit the FDA website at: http://www.fda.gov/medwatch/safety/2007/safety07.htm#PDE5, http://www.fda.gov/cder/consumerinfo/viagra/default.htm, http://www.fda.gov/cder/foi/label/2007/020895s027lbl.pdf, http://www.fda.gov/cder/drug/infopage/cialis/default.htm, http://www.fda.gov/cder/foi/label/2007/021368s012lbl.pdf, http://www.fda.gov/cder/drug/infopage/vardenafil/default.htm and http://www.fda.gov/cder/foi/label/2007/021400s010lbl.pdf.
Pending revision, the material in this section should be considered in light of more recently available information in the MEDWATCH notification at the beginning of this monograph.
To facilitate attainment of a sexually functional erection in males with erectile dysfunction (ED, impotence).
Most experts currently recommend that selective PDE type 5 inhibitors be offered as first-line therapy for erectile dysfunction unless contraindicated. Insufficient evidence to support the superiority of one selective PDE type 5 inhibitor over another.
Symptomatic treatment (e.g., to improve exercise capacity) of pulmonary arterial hypertension (PAH; WHO group I pulmonary hypertension).
Precise role (alone and combined with other therapies) remains to be fully elucidated. Whether long-term sildenafil therapy has a beneficial effect on mortality remains to be established; some preliminary data suggest a survival benefit.
Administer orally no more than once daily.
Administer about 1 hour (range: 4 hours to 30 minutes) before sexual activity.
Administration with a high-fat meal may delay the onset of action.
Administer orally 3 times daily (approximately 4–6 hours apart) without regard to meals.
Pending revision, the material in this section should be considered in light of more recently available information in the MEDWATCH notification at the beginning of this monograph.
Available as sildenafil citrate; dosage expressed in terms of sildenafil.
Initially, 50 mg. Depending on effectiveness and tolerance, increase dosage to a maximum of 100 mg or decrease to 25 mg.
20 mg 3 times daily. Efficacy of lower dosages not established.
Maximum 100 mg daily.
Dosages up to 80 mg 3 times daily have been studied but have not been more effective than recommended dosage of 20 mg 3 times daily.
Reduce initial dose to 25 mg.
No dosage adjustments necessary for mild to moderate hepatic impairment (Child-Pugh class A and B). Not studied in severe hepatic impairment (Child-Pugh class C).
If Clcr is <30 mL/minute, reduce initial dose to 25 mg.
No dosage adjustment needed, even in severe impairment (Clcr <30 mL/minute).
Reduce initial dose to 25 mg in men ≥65 years of age.
Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.
Related Learning Centers |
![]() |
![]() |
